Aviso de isenção de responsabilidade: Este PDF foi gerado automaticamente a partir de conteúdos selecionados de nossas bases de dados. Essa funcionalidade é fornecida somente para sua conveniência e não deve nunca substituir o PDF escaneado originalmente. Nem a Cengage Learning nem suas licenciadas atestam ou garantem de alguma maneira esses PDFs gerados automaticamente. O PDF é gerado automaticamente "NO FORMATO EM QUE SE ENCONTRA" e "DE ACORDO COM A DISPONIBILIDADE" e não é mantido em nosso sistema. A CENGAGE LEARNING E SUAS LICENCIADAS ESPECIFICAMENTE SE ISENTAM DE RESPONSABILIDADE SOBRE QUALQUER GARANTIA EXPRESSA OU IMPLÍCITA, SEM LIMITAÇÕES, INCLUSIVE GARANTIAS DE DISPONIBILIDADE, PRECISÃO, PONTUALIDADE, COMPLETUDE, LEGALIDADE, COMERCIABILIDADE OU ADEQUAÇÃO A UM PROPÓSITO ESPECÍFICO. O uso que você fizer do PDF automático está sujeito a todas as restrições de uso inclusas no Contrato de Licença e Assinatura da Cengage Learning e/ou dos Termos e Condições da Gale Virtual Reference Library e, ao usar a funcionalidade de PDF automático, você concorda em renunciar a qualquer alegação contra a Cengage Learning ou suas licenciadas pelo uso da funcionalidade de PDF automático e qualquer resultado derivado desta. Accuracy of plasma interleukin-18 and adiponectin concentrations in predicting metabolic syndrome and cardiometabolic disease risk in middle- age Brazilian men Alessandro de Oliveira, Helen Hermana Hermsdorff, Paula G. Cocate, Eliziaria C. Santos, Josefina Bressan and Antonio Jose Natali Applied Physiology, Nutrition, and Metabolism. 40.10 (Oct. 2015): p1048+. DOI: http://dx.doi.org/10.1139/apnm-2014-0487 Copyright: COPYRIGHT 2015 NRC Research Press http://pubs.nrc-cnrc.gc.ca/rp-ps/journalDetail.jsp?jcode=apnm&lang=eng Resumo: The aims of this cross-sectional study were to explore the ability of serum interleukin 18 (IL-18) and adiponectin to identify metabolic syndrome (MetS), and to verify their association with an index of central lipid overaccumulation (lipid accumulation product (LAP)) and cardiometabolic risk factors in a population of middle-aged Brazilian men. A group of 218 apparently healthy middle-aged Brazilian men (age, 50.3 [+ or -] 4.97 years) underwent anthropometric, clinical, sociodemographic, and standard serum biochemical assessments. LAP was calculated and the study participants were categorized into 3 groups according to serum IL-18 and adiponectin cut- points tertiles to verify the association of these biomarkers with cardiometabolic risk factors. The MetS group had more less active (p = 0.03) and obese (p < 0.01) individuals who exhibited higher IL-18 (p < 0.01) and lower adiponectin (p < 0.01) than did those in the group with no MetS. After adjustments (age, smoking, alcohol consumption, physical activity level, and total body fat), serum IL-18 [greater than or equal to] 336.4 [micro]g/mL was an independent factor for MetS occurrence and it was directly associated with LAP ([greater than or equal to]51.28), central obesity, hypertriglyceridemia, and hypertension (p < 0.05), but not with high-density lipoprotein cholesterol (HDL-C). Serum adiponectin [greater than or equal to] 7.02 [micro]g/mL was negatively associated with MetS occurrence, LAP, hypertriglyceridemia, and low HDL-C (p < 0.05), but not with central obesity and hypertension. In conclusion, both IL-18 and adiponectin demonstrated the ability to identify MetS in this population, with IL-18 being more accurate. The association of these biomamarkers with LAP and cardiometabolic risk factors highlights its relevance as a diagnostic tool. Key words: cardiometabolic risk, adipokines, interleukins, metabolic syndrome. Cette etude transversale se propose d'explorer l'utilisation de l'interleukine 18 (<<IL-18>>) et de l'adiponectine dans le serum pour identifier le syndrome metabolique (<<MetS>>) et de verifier leur association avec un indice de suraccumulation centrale de lipides (produit de l'accumulation des lipides (<<LAP>>)) et les facteurs de risque cardiometabolique dans une population de Bresiliens masculins d'age moyen. Un groupe de 218 Bresiliens masculins d'age moyen (age : 50,3 [+ or -] 4,97 ans) et apparemment en bonne sante participent a des seances de mesures anthropologiques, cliniques, sociodemographiques et serobiochimiques standards. On evalue LAP et on divise les participants en trois groupes selon les tertiles des valeurs seriques d'IL-18 et d'adiponectine pour verifier l'association de ces biomarqueurs avec les facteurs de risque cardiometabolique. Le groupe MetS comprend plus de personnes moins actives (p = 0,03) et obeses (p < 0,01) avec des valeurs plus elevees d'IL-18 (p < 0,01) et plus faibles d'adiponectine (p < 0,01) que le groupe exempt de MetS. Apres ajustements (age, tabagisme, consommation d'alcool, niveau d'activite physique et gras corporel total), une valeur serique d'IL-18 [greater than or equal to] 336,4 pg/mL constitue un facteur independant de l'occurrence de MetS et est associee directement a LAP ([greater than or equal to] 51,28), a l'obesite centrale, a l'hypertriglyceridemie et a l'hypertension (p < 0,05), mais pas au cholesterol de haute densite (<<HDL-C>>). Une valeur serique d'adiponectine > 7,02 [micro]g/mL est negativement associee a l'occurrence de MetS, a LAP, a l'hypertriglyceridemie et a un faible HDL-C (p < 0.05) et n'est pas associee a l'obesite centrale et a l'hypertension (p < 0,05). En conclusion, l'IL-18 et l'adiponectine peuvent etre utilisees pour verifier la presence de MetS dans cette population, l'IL-18 etant plus precise. L'association de ces biomarqueurs avec LAP et les facteurs de risque cardiometabolique souligne sa pertinence comme outil de diagnostic. [Traduit par la Redaction] Mots-cles: risque cardiometabolique, adiponectine, interleukine, syndrome metabolique. Texto completo: Introduction Metabolic syndrome (MetS) is a combination of cardiovascular and metabolic risk factors, including high blood pressure, hyperglycemia, dyslipidemia, and, mainly, central obesity, which predispose individuals to cardiovascular diseases and type 2 diabetes (Alberti et al. 2009; International Diabetes Federation (IDF) 2006; Gallagher et al. 2008). The prevalence of MetS and its components may be influenced by differences in genetic background, diet, levels of physical activity, population age, sex, and levels of over- and undernutrition (Cameron et al. 2004). Improvement in the accuracy of identification of individuals at risk of MetS could improve detection and prevention of related diseases. Given the complexity and multifactorial nature of MetS, other diagnosis criteria such as those based on the levels of inflammatory biomarkers are proposed to increase the accuracy of its diagnosis in clinical practice (Licht et al. 2013; Osgood et al. 2013). The importance of the inflammatory mechanisms in cardiometabolic disorders, as well as the relevance of the pro-inflammatory and anti-inflammatory balance in the prevention of